ClinicalTrials.gg
CompletedNCT07429045Updated Feb 24, 2026

A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body

A Phase 1 interventional study of AMG 133 in Overweight and Obesity, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-24.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing maridebart cafraglutide in Obesity — 9 open to participants now, 17 under way, 11 of them phase 3. maridebart cafraglutide · Obesity.

Enrollment
27th of 28
44 · median 275
Started
2025
with 10 others
Phase 1
14 of 28
3 open now
Registered
17th of 28
by date
Lead sponsor
28 of 28
Amgen

Among the 28 studies testing maridebart cafraglutide in Obesity, this one is the 27th largest by enrollment, is one of 11 that started in 2025, is one of 14 in phase 1, and was the 17th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 28 studies testing maridebart cafraglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About maridebart cafraglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing maridebart cafraglutide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the pharmacokinetics of a single subcutaneous (SC) dose of AMG 133 in participants with various degrees of renal impairment compared to participants with normal renal function.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • Obesity
  • AMG 133
  • Maridebart cafraglutide
  • MariTide
04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 44 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants in Groups 1 to 5

  1. Male or female, of any race, between 18 and 75 years of age, inclusive.

    a. Females must not be pregnant or lactating.

  2. > 22.0 kg/m2.
  3. Eligible participants classified based on at screening and established need for renal replacement therapy as applicable.

    Participants with Normal Renal Function

  4. In good health as determined by no findings from medical history, physical examination, vital signs measurements, 12-lead ECGs, and clinical laboratory evaluations.

    Participants with Renal Impairment

  5. Participants with renal impairment may have medical findings consistent with their renal dysfunction.

Exclusion criteria

Exclusion Criteria

All Participants in Groups 1 to 5

  1. History or evidence of disorder, condition, or disease not otherwise excluded that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  2. History or evidence of endocrine disorder.
  3. History of acute or chronic pancreatitis within 1 year prior to check-in, or elevation in serum lipase/amylase (> 2 x ) at screening, or fasting serum triglyceride level of > 500 mg/dL at screening.
  4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  5. History of , intolerance, or allergy to AMG 133 or its ingredients or to related/similar compounds.
  6. Active liver disease or hepatic dysfunction.
  7. Clinically significant hyperkalemia.
  8. Current use or prior use of any GLP-1R agonist, or GIPR agonist or antagonist within the past 3 months prior to check-in.
  9. Participant has received a dose of an drug within the past 30 days or 5 half-lives prior to AMG 133 dosing.
  10. Have previously completed or withdrawn from this study or any other study investigating AMG 133 or have previously received the investigational product.

    Participants with Normal Renal Function (Group 1)

  11. History of active diabetes or evidence based on of > 6.5% (> 48 mmol/mol).
  12. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives (whichever is longer) before check-in.
  13. A history of renal disease or renal injury as indicated by medical history or an abnormal renal function profile.

    Participants with Renal Impairment (Groups 2 to 5)

  14. Participants who have a current, functioning organ transplant and/or are on .
  15. Participants on the national transplant list who anticipate receiving an organ transplant within 6 months of check-in.
  16. History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.
  17. Use of any over-the-counter or prescription medications within 30 days or 5 half-lives before check-in.
  18. History of poorly controlled diabetes or evidence based on hemoglobin A1C of > 11% (> 97 mmol/mol).
  19. Active of any type.
  20. A change in renal disease status within 30 days of screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Group 1: Normal renal function

    Participants with an estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133

  • Experimental
    Group 2: Mild renal impairment

    Participants with an eGFR of 60 to \< 90 mL/min will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133

  • Experimental
    Group 3: Moderate renal impairment

    Participants with an eGFR of 30 to \< 60 mL/min will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133

  • Experimental
    Group 4: Severe renal impairment and kidney failure not receiving hemodialysis

    Participants with an eGFR of \< 30 mL/min will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133

  • Experimental
    Group 5: Kidney failure receiving hemodialysis

    Participants with an eGFR of \< 15 mL/min will receive a single dose of AMG 133 as a SC injection.

    Drug: AMG 133

Interventions

  • Participants will receive one dose of AMG 133 as a SC injection.

    Also known as: Maridebart cafraglutide

07

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of AMG 133

    Time frame: Up to Day 120

  2. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133

    Time frame: Up to Day 120

  3. AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133

    Time frame: Up to Day 120

Secondary outcomes

  1. Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 to Day 120

  2. Number of Participants who Experienced Serious AEs (SAEs)

    Time frame: Screening to Day 120 (up to 148 days)

  3. Number of Participants with Positive Anti-AMG 133 Antibody Formation

    Time frame: Up to Day 120

08

Study locations

5 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • AdvancedPharma CR LLC
    Miami, Florida 33147-4040, United States
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • Omega Research Group, LLC - Orlando
    Orlando, Florida 32806-1133, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809-3017, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Nov 2025, 8 months.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is below that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Mar 11, 2025
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07429045
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Mar 11, 2025
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Last update
Feb 24, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion